News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apollo Endosurgery To Report Second Quarter 2017 Financial Results On August 1, 2017



7/26/2017 8:51:02 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it plans to release its second quarter 2017 financial results on Tuesday, August 1, 2017 after the U.S. stock markets close.

Apollo will hold a conference call on Tuesday, August 1, 2017 at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (877) 548-7914 for domestic callers and (719) 457-6931 for international callers. The conference ID number is 2382032.

A telephonic replay of the call will be available until August 8, 2017. The replay dial-in numbers are (844)-512-2921 for domestic callers and (412) 317-6671 for international callers. Please use the replay conference ID number 2382032.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 80 countries today.

Apollo’s common stock is traded on the NASDAQ Global Market under the symbol "APEN." For more information regarding Apollo Endosurgery, go to: www.apolloendo.com

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
Chief Financial Officer
investor-relations@apolloendo.com
or
The Ruth Group
Lee Roth or Zack Kubow, 646-536-7000
apolloendo@theruthgroup.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES